ArticleNature communications2021
Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 164 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
164 citing papers in PubMed, 3 syntheses or guidelines pooled it, 252 citations in OpenAlex.
- Unravelling novel microbial players in the breast tissue of TNBC patients: a meta-analytic perspective.NPJ biofilms and microbiomes · 2025Pooled it
- Genetically proxied gut microbiota and cancer risk: a scoping review of Mendelian randomization studies.Archives of public health = Archives belges de sante publique · 2025Pooled it
- Is the oral pathogen, Porphyromona gingivalis, associated to colorectal cancer?: a systematic review.BMC cancer · 2025Pooled it
- The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial.Cancer prevention research (Philadelphia, Pa.) · 2025Trial
- Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.International journal of cancer · 2022Trial
- Review
- Article
- Functional Heterogeneity ofMicroorganisms · 2026Article
- Protocol digest of a randomized controlled trial comparing transverse colectomy with extended right hemicolectomy for Stage II/III transverse colon cancer: JCOG2304 (TACTICS).Japanese journal of clinical oncology · 2026Article
- Prior cholecystectomy may identify a biologically aggressive subset of RAS-mutated proximal colon cancer: A 13-year retrospective cohort study.Surgery today · 2026Article
- Gut microbiota in health and disease.Molecular biomedicine · 2026Review
- Differential Prognostic Impact of Prior Cholecystectomy Between Proximal and Distal Colorectal Cancer: A 12-Year Retrospective Cohort Study of 3487 Consecutive Patients.Annals of gastroenterological surgery · 2026Article
- Pathophysiology of colitis-associated colorectal cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Gemella morbillorum Promotes Colorectal Carcinogenesis: LPBDCP-Mediated Invasion Activates Ras Signaling and Destabilizes p53.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The gut microbiome and ageing trajectories: mechanisms and clinical implications.Nature reviews. Endocrinology · 2026Review
- Bone marrow mesenchymal stem cells synergize with fusobacterium nucleatum to drive colorectal tumorigenesis via gut microbiome dysbiosis.Gut pathogens · 2026Article
- Review
- Engineering probiotics as living biotherapeutics: a novel paradigm of restoring physiological barriers via targeted short-chain fatty acid delivery.Science China. Life sciences · 2026Article
- Parvimonas micra promotes carcinogenesis of colorectal cancer through phenyllactic acid-induced DNA damage.Clinical and translational medicine · 2026Article
- Sucralose and the Gut-Immune Axis: Emerging Evidence Linking Dysbiosis, Barrier Alterations, and Implications for Colitis and Colorectal Cancer Immunotherapy.Biomedicines · 2026Review
104 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence is revealing that alterations in gut microbiota are associated with colorectal cancer (CRC). However, very little is currently known about whether and how gut microbiota alterations are causally associated with CRC development. Here we show that 12 faecal bacterial taxa are enriched in CRC patients in two independent cohort studies. Among them, 2 Porphyromonas species are capable of inducing cellular senescence, an oncogenic stress response, through the secretion of the bacterial metabolite, butyrate. Notably, the invasion of these bacteria is observed in the CRC tissues, coinciding with the elevation of butyrate levels and signs of senescence-associated inflammatory phenotypes. Moreover, although the administration of these bacteria into Apc
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.